Home > Dermatology > AAD 2019 > Pearls of the Posters > Plaque psoriasis – Efficacy of guselkumab

Plaque psoriasis – Efficacy of guselkumab

Conference
AAD 2019
Trial
Phase 3, VOYAGE 1, VOYAGE 2

Guselkumab is a fully human monoclonal antibody that acts as a blocker of IL-23. The ongoing pivotal phase 3 trials VOYAGE 1 and 2 have demonstrated significant efficacy of guselkumab for the treatment of moderate-to-severe plaque psoriasis in comparison with an active comparator and placebo. The current investigation analysed pooled data from VOYAGE 1 and 2 with regard to long-term efficacy in patients with or without psoriatic arthritis (PsA) [1].

In VOYAGE 1, over 800 patients were treated with either (1) 100 mg guselkumab at week 0, 4, and 12, and then every 8 weeks, (2) placebo at week 0, 4, and 12, followed by guselkumab at week 16 and 20, and every 8 weeks thereafter; or (3) adalimumab until week 47. From week 52 onwards, all patients received 100 mg guselkumab open-label until week 156. The study design for the nearly 1,000 patients in VOYAGE 2 was similar, but the open-label guselkumab phase in weeks 76-156 was preceded by a randomised withdrawal....



Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on